is MESO getting beat to the punch on GvHD??
https://finance.yahoo.com/news/incytes-jakafi-gets-fda-approval-185021493.htmlThe U.S. Food and Drug Administration on Friday approved Incyte Corp's treatment for acute Graft versus Host disease (GvHD), an inflammatory response by the immune system after a bone marrow transplant. The drug, ruxolitinib, sold under the brandThe U.S. Food and Drug Administration on Friday approved Incyte Corp's treatment for acute Graft versus Host disease (GvHD), an inflammatory response by the immune system after a bone marrow transplant. The drug, ruxolitinib, sold under the brandfinance.yahoo.com
Cell Therapy News/Articles, page-450
-
- There are more pages in this discussion • 17,394 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.13 |
Change
-0.025(2.17%) |
Mkt cap ! $1.284B | |||
| Open | High | Low | Value | Volume |
| $1.15 | $1.16 | $1.11 | $7.363M | 6.488M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 5 | 94863 | $1.13 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.13 | 5000 | 2 |
View Market Depth
| Last trade - 16.10pm 26/07/2024 (20 minute delay) ? |
| MSB (ASX) Chart |